Cell Therapy and Transplantation in Parkinsons Disease
-
Olle Lindvall
Abstract
Transplanted human fetal dopamine neurons can reinnervate the striatum in patients with Parkinson's disease (PD). Recent findings using positron emission tomography indicate that the grafts are functionally integrated and restore dopamine release in the patient's striatum. The grafts can exhibit long-term survival without immunological rejection and despite an ongoing disease process and continuous antiparkinsonian drug treatment. In the most successful cases, patients have been able to withdraw L-dopa treatment after transplantation and resume an independent life. About two-thirds of grafted patients have shown clinically useful, partial recovery of motor function. The major obstacle for the further development of this cell replacement strategy is that large amounts of human fetal mesencephalic tissue are needed for therapeutic effects. Stem cells hold promise as a virtually unlimited source of self-renewing progenitors for transplantation. The possibility to generate dopamine neurons from such cells is now being explored using different approaches. However, so far the generated neurons have survived poorly after transplantation in animals.
Copyright © 2001 by Walter de Gruyter GmbH & Co. KG
Articles in the same Issue
- IFCC/ Beckman Coulter Inc. Conference Frontiers in Molecular Basis of Diseases: Cell Biology of Neuronal Dysfunction, Paris, October 12-13, 2000
- Distribution of Cellular Prion Protein in Normal Human Cerebral Cortex – Does It Have Relevance to Creutzfeldt-Jakob Disease?
- Caspase-3 Apoptotic Signaling Following Injury to the Central Nervous System
- Parkinsons Disease and other α-Synucleinopathies
- Aggregation-Dependent Interaction of the Alzheimers β-Amyloid and Microglia
- β-Amyloid-Induced Cytotoxicity, Peroxide Generation and Blockade of Glutamate Uptake in Cultured Astrocytes
- Protein S-100B: A Serum Marker for Ischemic and Infectious Injury of Cerebral Tissue
- Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software
- The Intrathecal Humoral Immune Response: Laboratory Analysis and Clinical Relevance
- Source of Endothelin-1 in Subarachnoid Hemorraghe
- Polymorphism of Apoprotein E (APOE), Methylenetetrahydrofolate Reductase (MTHFR) and Paraoxonase (PON1) Genes in Patients with Cerebrovascular Disease
- Neurotrophic Factor Therapy – Prospects and Problems
- Cell Therapy and Transplantation in Parkinsons Disease
- Matrix Metalloproteinases: Potential Therapeutic Target in Spinal Cord Injury
Articles in the same Issue
- IFCC/ Beckman Coulter Inc. Conference Frontiers in Molecular Basis of Diseases: Cell Biology of Neuronal Dysfunction, Paris, October 12-13, 2000
- Distribution of Cellular Prion Protein in Normal Human Cerebral Cortex – Does It Have Relevance to Creutzfeldt-Jakob Disease?
- Caspase-3 Apoptotic Signaling Following Injury to the Central Nervous System
- Parkinsons Disease and other α-Synucleinopathies
- Aggregation-Dependent Interaction of the Alzheimers β-Amyloid and Microglia
- β-Amyloid-Induced Cytotoxicity, Peroxide Generation and Blockade of Glutamate Uptake in Cultured Astrocytes
- Protein S-100B: A Serum Marker for Ischemic and Infectious Injury of Cerebral Tissue
- Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software
- The Intrathecal Humoral Immune Response: Laboratory Analysis and Clinical Relevance
- Source of Endothelin-1 in Subarachnoid Hemorraghe
- Polymorphism of Apoprotein E (APOE), Methylenetetrahydrofolate Reductase (MTHFR) and Paraoxonase (PON1) Genes in Patients with Cerebrovascular Disease
- Neurotrophic Factor Therapy – Prospects and Problems
- Cell Therapy and Transplantation in Parkinsons Disease
- Matrix Metalloproteinases: Potential Therapeutic Target in Spinal Cord Injury
